AVXL
NASDAQAnavex Life Sciences Corp.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks68-72%
2026-04-192026-10-11
Mix5890d
- SEC Filings34(59%)
- Other15(26%)
- Earnings4(7%)
- Insider3(5%)
- Leadership1(2%)
- Market1(2%)
Latest news
25 items- SECSEC Form 8-K filed by Anavex Life Sciences Corp.8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X SyndromeAnavex now has open INDs in all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the safety, tolerability and pharmacokinetics of blarcamesine oral solution in adult males with Fragile X syndrome NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with significant unmet medical needs, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the Company may proceed with its planned clinical study under its Invest
- INSIDERSEC Form 3 filed by Anavex Life Sciences Corp.3 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
- INSIDERSEC Form 3 filed by Anavex Life Sciences Corp.3 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
- NEWSAVXL Shareholder Alert: November 30, 2026 Lead Plaintiff Deadline in Anavex Life Sciences Corp. Securities Class Action - Contact Levi & KorsinskyNEW YORK CITY, NY / ACCESS Newswire / October 2, 2026 / Levi & Korsinsky, LLP notifies pension funds, ERISA plan fiduciaries, asset managers, and other institutional investors in Anavex Life Sciences Corp. (NASDAQ:AVXL) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between November 26, 2025 and August 28, 2026. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.AVXL fell 5.55%, or $0.18 per share, on May12, 2026 late-filing notice, then dropped another 6.35%, or $0.19 per share, on August 31, 2026. To be considered for lead plaintiff, investors must file by N
- INSIDERSEC Form 4 filed by PFO & Treasurer Boenisch Sandra4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Changes in Control of Registrant, Submission of Matters to a Vote of Security Holders8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual MeetingNEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company’s 2026 Annual Meeting of Stockholders ("Annual Meeting"), Anavex stockholders have voted to elect all six of its director nominees – Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Mr. Gautam Patel, Dr. Adrian Senderowicz and Dr. Claus van der Velden. Dr. Jiong Ma, Independent Chair of the Board, stated, "On behalf of the ne
- SECSEC Form DFAN14A filed by Anavex Life Sciences Corp.DFAN14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
- SECSEC Form DFAN14A filed by Anavex Life Sciences Corp.DFAN14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
- PRPVG Asset Management Announces Plan for First 100 Days at Anavex Life SciencesCENTENNIAL, Colo., Sept. 18, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of 337,663 shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) ("Anavex" or the "Company"), announced its plan following its anticipated success in the Company’s upcoming proxy vote. PVG management is optimistic that its slate of highly qualified director candidates will win approval from shareholders, particularly in light of the recent recommendation from Glass Lewis that Anavex shareholders vote the GOLD Universal Proxy Card. With a focus on results, PVG’s director nominees intend to take the following actions in the first 100 days: Leadership and management: Hire an experienced CEO
- SECSEC Form DFAN14A filed by Anavex Life Sciences Corp.DFAN14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
- PRGlass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for Change-- Proxy advisor recommends voting "FOR" two of PVG’s director nominees and "AGAINST" two incumbent director nominees including the board’s current chair on the GOLD Universal Proxy Card – -- PVG encourages stockholders to vote to elect all six of its director nominees by voting the GOLD Universal Proxy Card to help the Company realize the full potential of its valuable assets -- CENTENNIAL, Colo., Sept. 17, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of 337,663 shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) ("Anavex" or the "Company"), announced that leading independent proxy advisory firm Glass Lewis & Co. ("Glass Lewis") recommended that AVXL stockh
- SECSEC Form DEFA14A filed by Anavex Life Sciences Corp.DEFA14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- SECSEC Form DFAN14A filed by Anavex Life Sciences Corp.DFAN14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
- PRPVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance-- Yet ISS gives Anavex Board a free pass on years of failed governance and shareholder value destruction by supporting the current board’s nominees – -- It’s too little, too late after a few months of the incumbent board’s half-measures, so stockholders are encouraged to vote the GOLD Universal Proxy Card to elect PVG’s six nominees to help Anavex realize the full potential of its valuable assets while there’s still time -- CENTENNIAL, Colo., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of 337,663 shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) ("Anavex" or the "Company") is troubled that Institutional Shareholder Services ("ISS") recently sup
- SECSEC Form DEFA14A filed by Anavex Life Sciences Corp.DEFA14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- SECSEC Form DFAN14A filed by Anavex Life Sciences Corp.DFAN14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
- PRPVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy CampaignCENTENNIAL, Colo., Sept. 10, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (NASDAQ:AVXL) ("Anavex" or the "Company"), today announced that it will host an investor conference call to discuss its campaign for change in the Anavex Board of Directors at the upcoming 2026 Annual Meeting of Stockholders. During the call, PVG will discuss its views regarding the Company's recent performance, corporate governance, capital markets strategy, leadership transition, clinical development priorities, and the rationale for electing PVG's six highly qualified nominees to the Company's Board of Directors. Investor Call Details Date: Wednesday,
- SECSEC Form DFAN14A filed by Anavex Life Sciences Corp.DFAN14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
- SECAnavex Life Sciences Corp. filed SEC Form 8-K: Other Events8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRPVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL)CENTENNIAL, Colo., Sept. 09, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (NASDAQ:AVXL, Anavex", or the ", Company", )), believes the Anavex Board of Directors should be replaced and an experienced CEO should be hired. The "rookie" CEO held five positions across four organizations in seven years, none held longer than about 27 months.(1) On 27 February 2026, during her tenure as Aardvark's EVP of Regulatory Affairs, that company announced a voluntary pause of its Phase 3 HERO trial.(1) This was the first big decision of the Anavex Board after firing the CEO in April 2026. Fellow Stockholders, we need your support to turn Anavex a
- SECSEC Form DEFA14A filed by Anavex Life Sciences Corp.DEFA14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)
- PRAnavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ETNEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced it will host a conference call at 4:00 PM ET on Wednesday, September 9, 2026, during which Interim CEO Terrie Kellmeyer, Ph.D., will discuss the Company’s clinical development strategy and priorities. Anavex Investor Call Information: A link to the live webcast of the conference call will be available on Anavex’s investor relations website at anavex.com/investors.The conference call can also be accessed by d
- SECSEC Form DFAN14A filed by Anavex Life Sciences Corp.DFAN14A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)
AVXL FAQ
6 questionsWhat does Anavex Life Sciences Corp. do?
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The...Where does AVXL stock trade?
Anavex Life Sciences Corp. (AVXL) is listed on NASDAQ.What sector and industry is AVXL in?
Anavex Life Sciences Corp. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about AVXL?
Anavex Life Sciences Corp. has had 6 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $2000.00 price target on 2026-05-04. Recent price targets range from $1100.00 to $4200.00.What companies are similar to AVXL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare AVXL side-by-side with any of them on Quantisnow.How can I track AVXL on Quantisnow?
Quantisnow aggregates Anavex Life Sciences Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVXL to receive live email and push alerts on every new disclosure.